Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Sun Pharma Said to Seek Takeover Financing, Eye Meda Deal
Bloomberg
Saturday, June 1, 2013 - 1:00pm
tags:
Sun Pharma, Meda, M&A
New Approvals Spark a Melanoma Drug Battle
Motley Fool
Saturday, June 1, 2013 - 12:48pm
tags:
melanoma, GSK, Tafinlar, Mekinist, Roche, Bristol-Myers Squibb
3 FDA Stories You Missed This Week
Motley Fool
Saturday, June 1, 2013 - 12:46pm
tags:
Merck, suvorexant, insomnia, sleep aid, hypnotics, Celgene, Abraxane, prostate cancer, Glaxo, Tafinlar, dabrafenib, melanoma
ASCO '13: Array Drug First to be Effective Against Melanoma of the Eye
The Street
Saturday, June 1, 2013 - 12:44pm
tags:
Array Biopharma, melanoma, ocular melanoma, selumetinib, AstraZeneca
Erbitux Tops Roche’s Avastin for Colon Cancer Survival
Bloomberg
Saturday, June 1, 2013 - 12:42pm
tags:
Erbitux, Roche, Avastin, colon cancer, Merck KGaA
Olaparib in Patients With BRCA Mutated Platinum-Sensitive Relapsed Serous Ovarian Cancer: New Data Presented at ASCO
Yahoo/BusinessWire
Saturday, June 1, 2013 - 12:25pm
tags:
olaparib, ovarian cancer, AstraZeneca
Bristol drug shrinks melanoma in 31 pct of trial patients
Reuters
Saturday, June 1, 2013 - 12:24pm
tags:
nivolumab, Bristol-Myers Squibb, melanoma
Where to Invest for More Health-Care Exposure
Motley Fool
Saturday, June 1, 2013 - 12:22pm
tags:
Pfizer, Merck, JNJ
AbbVie Ups Ante on JAK Inhibitor
Motley Fool
Saturday, June 1, 2013 - 12:21pm
tags:
AbbVie, rheumatoid arthritis, JAK inhibitors
NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual Meeting
Yahoo/PR Newswire
Saturday, June 1, 2013 - 12:19pm
tags:
NewLink Genetics, tergenpumatucel-L, non-small cell lung cancer
Exelixis Announces Presentation of Updated Phase 2 Data for Cabozantinib in Men with Heavily-Pretreated Metastatic Castration-Resistant Prostate Cancer
Yahoo/BusinessWire
Saturday, June 1, 2013 - 12:17pm
tags:
Exelixis, cabozantinib, prostate cancer
ARIAD Presents Analysis of Cardiovascular Risk Profile of Patients from Pivotal PACE Trial of Iclusig (Ponatinib)
Yahoo/BusinessWire
Saturday, June 1, 2013 - 12:16pm
tags:
Iclusig, Ariad Pharmaceuticals, leukemia
Progenics Pharmaceuticals' Data From a Phase 1 Study of PSMA ADC Presented at ASCO 2013
Yahoo/GlobeNewsWire
Saturday, June 1, 2013 - 12:15pm
tags:
Progenics Pharmaceuticals, PSMA ADC, prostate cancer
CTI Reports Final Results from Cooperative Group and NCI-Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast Cancer
Yahoo/PR Newswire
Saturday, June 1, 2013 - 12:13pm
tags:
Brostallicin, breast cancer, Cell Therapeutics
Amgen melanoma drug improved survival by 21 pct in interim look
Reuters
Saturday, June 1, 2013 - 12:12pm
tags:
Amgen, T-Vec, Talimogene Laherparepvec, melanoma
3 Reasons I’m Still Buying After a 5-Year 775% Return
Motley Fool
Saturday, June 1, 2013 - 12:11pm
tags:
Jazz Pharmaceuticals
Was The Aetna News Overblown? Blue Cross Blue Shield Supports Questcor's H.P. Acthar Gel
Seeking Alpha
Saturday, June 1, 2013 - 12:10pm
tags:
Aetna, Questcor Pharmaceuticals, H.P. Acthar Gel
Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against AVEO Pharmaceuticals, Inc.
Yahoo/BusinessWire
Saturday, June 1, 2013 - 12:09pm
tags:
Aveo Pharmaceuticals, lawsuits
(video) Cramer: New Cancer Fighting Biotech
CNBC
Saturday, June 1, 2013 - 12:08pm
tags:
Celldex
Why Gilead Sciences Is Poised to Keep Poppin
Motley Fool
Saturday, June 1, 2013 - 12:06pm
tags:
Gilead Sciences

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.